A. Drollmann

发表

Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma

H. Derendorf, R. Nave, A. Drollmann, 2006, European Respiratory Journal.

Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling

R. Woessner, A. Drollmann, Hilmar Schiller, 2021, Clinical and translational science.

Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers.

A. Drollmann, W. Wurst, C. Leach, 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.

L. Boulet, P. O'Byrne, D. Cockcroft, 2016, The Journal of allergy and clinical immunology.

Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.

C. Fogarty, A. Drollmann, Helen Hattersley, 2011, Respiratory medicine.

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial

H. Marshall, K. Kostikas, J. Wild, 2022, Respiratory Research.

Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma.

L. Boulet, A. Drollmann, L. Fabbri, 2006, Respiratory medicine.

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

Dave Singh, A. Drollmann, K. Beeh, 2012, International journal of chronic obstructive pulmonary disease.

Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study

S. Khindri, R. Woessner, A. Drollmann, 2011, BMC pulmonary medicine.

A Thorough QT Study on the Effect of Indacaterol on Cardiac Safety in Healthy Subjects.

S. Khindri, A. Drollmann, R. Sabo, 2009, ATS 2009.

Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3.

Imad Hanna, A. Drollmann, E. Greco, 2021, Pulmonary pharmacology & therapeutics.

Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma.

C. G. Langdon, A. Drollmann, M. Alexander, 2005, Respiratory medicine.

Once-daily NVA 237 improves exercise tolerance from the first dose in patients with COPD : the GLOW 3 trial

Dave Singh, A. Drollmann, K. Beeh, 2012 .

Equivalent Pharmacokinetics of the Active Metabolite of Ciclesonide With and Without Use of the AeroChamber Plus™ Spacer for Inhalation

R. Nave, A. Drollmann, V. Steinijans, 2006, Clinical pharmacokinetics.

Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide.

A. Drollmann, W. Wurst, V. Steinijans, 2002, The Journal of clinical endocrinology and metabolism.

Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD).

D. Renard, A. Drollmann, G. Kaiser, 2012, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.

O. Heudi, H. Tillmann, A. Drollmann, 2020, Pulmonary pharmacology & therapeutics.

Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin.

R. Nave, A. Drollmann, V. Steinijans, 2005, International journal of clinical pharmacology and therapeutics.

The Effect of Indacaterol Maleate on Dynamic Lung Hyperinflation in Patients with COPD.

S. Khindri, A. Drollmann, K. Beeh, 2009, ATS 2009.

Validation of computational fluid dynamics in CT-based airway models with SPECT/CT.

Wilfried De Backer, Paul M Parizel, Paul Germonpré, 2010, Radiology.

Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.

R. Woessner, M. Kaul, A. Drollmann, 2022, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD

A. Drollmann, K. Beeh, F. Wagner, 2011, COPD.

Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.

P. Pal, A. Drollmann, S. Uziel-Fusi, 2013, International journal of clinical pharmacology and therapeutics.

High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma.

R. Nave, A. Drollmann, S. Newman, 2006, Respiratory medicine.

A Randomized, Double-blind, Placebo-controlled, Multi-center, Two-period Crossover Study To Investigate The Bronchodilatory Effect Of NVA237 50µg Inhaled Once Daily In Patients With COPD

C. Fogarty, A. Drollmann, Helen Hattersley, 2010, Asian Test Symposium.

Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers.

A. Drollmann, I. Jones, S. Febbraro, 2014, International journal of clinical pharmacology and therapeutics.

Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis

M. Ben-Shoshan, M. Maurer, A. Drollmann, 2023, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Effect of Coadministered Ketoconazole, a Strong Cytochrome P450 3A4 Enzyme Inhibitor, on the Pharmacokinetics of Ciclesonide and its Active Metabolite Desisobutyryl-Ciclesonide

C. Gleiter, A. Drollmann, R. Nave, 2008, Clinical pharmacokinetics.

Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD

A. Drollmann, K. Beeh, F. Wagner, 2011, COPD.